MDM2 and cancer: Selinexor has been assessed in the preclinical setting for RR-MM and with other cancer treatments in combination with novel agents, including the Bcl2 inhibitor venetoclax, Bcl-xL inhibitors, azacitidine, tyrosine kinase inhibitors, topoisomerase inhibitors, the MDM2 inhibitor nutlin 3a, and immune checkpoint PD-1 inhibitors.